CO5540310A2 - Derivados de tri- y tetraazaacenaftileno como antagonista del receptor de crf - Google Patents

Derivados de tri- y tetraazaacenaftileno como antagonista del receptor de crf

Info

Publication number
CO5540310A2
CO5540310A2 CO03102138A CO03102138A CO5540310A2 CO 5540310 A2 CO5540310 A2 CO 5540310A2 CO 03102138 A CO03102138 A CO 03102138A CO 03102138 A CO03102138 A CO 03102138A CO 5540310 A2 CO5540310 A2 CO 5540310A2
Authority
CO
Colombia
Prior art keywords
substituted
alkyl
aryl
heteroaryl
hydrogen
Prior art date
Application number
CO03102138A
Other languages
English (en)
Inventor
Fabio Romano Di
Gabriella Gentile
Haddach Mustapha
Yves St-Denis
John Patrick Williams
Original Assignee
Neurocrine Inc
Sb Pharmco Puerto Rico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Inc, Sb Pharmco Puerto Rico filed Critical Neurocrine Inc
Publication of CO5540310A2 publication Critical patent/CO5540310A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

1.- Un compuesto que tiene la siguiente estructura: o un estereoisómero, precursor o una sal farmacéuticamente aceptable del mismo, caracterizado porque: A es un enlace o C=(Z); X es nitrógeno o CR3; Yes .N=, -N(R7)-, -C(R8)= o -O-; Z es O, S o NR9; R1 es alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo o heteroarilo sustituido; R2 es hidrógeno, alquilo, alquilo sustituido, alcoxi, tioalquilo, halo, ciano, haloalquilo;R3 es hidrógeno, alquilo, alquilo sustituido, halo o haloalquilo; R4 es hidrógeno, alquilo, alquilo sustituido, C(O)R1, arilo, arilo sustituido, heterociclo o heterociclo sustituido; R5 es hidrógeno, halógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, alcoxi, tioalquilo, C(O)R1, NR10R11 o ciano; R6 es hidrógeno, halógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, alcoxi, tioalquilo, C(O)R1, NR10R11 o ciano; R7 es hidrógeno, alquilo, alquilo sustituido C(O)R1, arilo, arilo sustituido, heteroarilo o heteroarilo sustituido; R8 es hidrógeno, halógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, alcoxi, tioalquilo, C(O)alquilo, NR10R11 o ciano; R9 es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo o heteroarilo sustituido; y R10 y R11 son iguales o diferentes y son independientemente hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido.2.- El compuesto de conformidad con la reivindicación 1, caracterizado además porque X es CR3.3.- El compuesto de conformidad con la reivindicación 1, caracterizado además porque X es nitrógeno.
CO03102138A 2001-05-21 2003-11-19 Derivados de tri- y tetraazaacenaftileno como antagonista del receptor de crf CO5540310A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29266001P 2001-05-21 2001-05-21

Publications (1)

Publication Number Publication Date
CO5540310A2 true CO5540310A2 (es) 2005-07-29

Family

ID=23125629

Family Applications (1)

Application Number Title Priority Date Filing Date
CO03102138A CO5540310A2 (es) 2001-05-21 2003-11-19 Derivados de tri- y tetraazaacenaftileno como antagonista del receptor de crf

Country Status (21)

Country Link
US (1) US7446108B2 (es)
EP (1) EP1392689B1 (es)
JP (1) JP2004530702A (es)
KR (1) KR20040018260A (es)
CN (1) CN1529705A (es)
AT (1) ATE343578T1 (es)
AU (1) AU2002257939B2 (es)
BR (1) BR0209947A (es)
CA (1) CA2450535A1 (es)
CO (1) CO5540310A2 (es)
CZ (1) CZ20033165A3 (es)
DE (1) DE60215637T2 (es)
ES (1) ES2274972T3 (es)
HU (1) HUP0400854A2 (es)
IL (1) IL158806A0 (es)
MX (1) MXPA03010635A (es)
NO (1) NO20035148D0 (es)
NZ (1) NZ529471A (es)
PL (1) PL367771A1 (es)
WO (1) WO2002094826A1 (es)
ZA (1) ZA200308810B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1704149B1 (en) 2004-01-06 2007-03-07 Taisho Pharmaceutical Co., Ltd Triaza-cyclopenta[cd]indene derivatives
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2756815A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Peri-fused pyrazolo-pyrimidine compounds
PT2440558E (pt) 2009-06-08 2015-08-27 Takeda Pharmaceutical Compostos de dihidropirrolonaftirridinona como inibidores de jak
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211063A (ja) * 1990-03-05 1992-08-03 Takeda Chem Ind Ltd 縮合三環性複素環化合物、その製造法、用途及び中間体
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EP0923582B1 (en) * 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
DE69903333T2 (de) * 1998-11-12 2003-08-07 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
GB0117395D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE60215637D1 (de) 2006-12-07
PL367771A1 (en) 2005-03-07
ZA200308810B (en) 2004-11-30
ATE343578T1 (de) 2006-11-15
NO20035148D0 (no) 2003-11-19
ES2274972T3 (es) 2007-06-01
EP1392689A1 (en) 2004-03-03
US7446108B2 (en) 2008-11-04
WO2002094826A1 (en) 2002-11-28
CA2450535A1 (en) 2002-11-28
DE60215637T2 (de) 2007-08-23
EP1392689B1 (en) 2006-10-25
IL158806A0 (en) 2004-05-12
CN1529705A (zh) 2004-09-15
CZ20033165A3 (cs) 2004-10-13
US20040198726A1 (en) 2004-10-07
BR0209947A (pt) 2004-04-27
MXPA03010635A (es) 2004-12-06
KR20040018260A (ko) 2004-03-02
AU2002257939B2 (en) 2006-08-24
JP2004530702A (ja) 2004-10-07
NZ529471A (en) 2005-12-23
HUP0400854A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
AR092490A2 (es) Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
BRPI0414084A (pt) composto, mistura, e, composição
CO5540310A2 (es) Derivados de tri- y tetraazaacenaftileno como antagonista del receptor de crf
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
MY135841A (en) Novel benzodioxoles
MY140680A (en) Hepatitis c virus inhibitors
DE602005023015D1 (de) Indolderivate als viruzide
ATE524522T1 (de) Xanthen-farbstoffe
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
CR6935A (es) Agentes del receptor b3-adrenergico y usos de los mismos
ATE338461T1 (de) Pyrazolpyrimidinfungizide
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
CO5160253A1 (es) Complejo de 1,4-benzodiazepinas sustituidas y sulfobutileter -7-ciclodextrina o 2-hidroxipropil-b-ciclodextrina .
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ECSP045222A (es) INHIBIDORES DE LA ADHESION CELULAR MEDIADA POR INTEGRINA aLb2
CO5160255A1 (es) DERIVADOS DE 4-OXO-3,5-DIHIDRO-4H-PIRIDAZINO[4,5-b]INDOL-1- CARBOXAMIDA Y COMPOSICIONES QUE LOS COMPRENDEN
ATE509911T1 (de) Verbindungen, die sich an die kleine furche von dna binden
ES2178382T3 (es) Compuestos de benciloxiprodigiosina.
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
CO5140085A1 (es) Derivados terapeuticos de benzamida

Legal Events

Date Code Title Description
FC Application refused